Dr Reddy Stock
Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'
 "Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit")
Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market
The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'
 "Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market")
Dr Reddy's declines 3% after China's regulator bans import of ADHD drug
Atomoxetine is used for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years.
 "Dr Reddy's declines 3% after China's regulator bans import of ADHD drug")
Dr Reddy's Labs hits record high on pact with Kainomyx for malaria drug
Dr Reddy's Laboratories shares reached their all time high at Rs 7,101 per share, surging 1.95 per cent at intraday levels on Wednesday
 "Dr Reddy's Labs hits record high on pact with Kainomyx for malaria drug")
Dr Reddy's Labs Q1 Preview: Market share loss in products to drag profits
Indian drugmaker, Dr Reddy's Laboratories is all set to deliver its financial performance for the first quarter of financial year 2024-25 (Q1FY25) on Saturday, July 27, 2024
 "Dr Reddy's Labs Q1 Preview: Market share loss in products to drag profits")
Earnings boost for Dr Reddy's Lab post consumer healthcare acquisition
In India, DRL has an OTC portfolio in the hydration, cough-cold-allergy, and skin care categories
Dr Reddy's rallies 4%; market cap touches Rs 1 trillion post Q3 results
With this, Dr Reddy's has become the third listed pharmaceutical company to achieve the Rs 1-trillion m-cap feat
Sensex, Nifty end flat; Dr Reddy's Labs drops 7%, L&T 5%, Adani Ent up 5%
CLOSING BELL: In the broader markets, the BSE SmallCap index outperformed the frontline indices with 0.68 per cent rise
 "Sensex, Nifty end flat; Dr Reddy's Labs drops 7%, L&T 5%, Adani Ent up 5%")
Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts
Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.
 "Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts")
New launches, regulatory go-ahead key triggers for Dr Reddy's
Sales in the US, its biggest market, accounting for 37 per cent of revenues, were up 8 per cent year-on-year (YoY) and 12 per cent sequentially, led by five new launches
 "New launches, regulatory go-ahead key triggers for Dr Reddy's")
Technical calls by Religare Broking: Buy Dr Reddy's Lab, Ramco Cements
Weekly Technical Recommendations by Religare Broking Ltd.
 "Technical calls by Religare Broking: Buy Dr Reddy's Lab, Ramco Cements")
Dr Reddy's Labs shines among pharma stocks, wins investor confidence
The Hyderabad-based company is an outlier among large pharmaceutical producers, having seen a jump in its stock price over the previous year
 "Dr Reddy's Labs shines among pharma stocks, wins investor confidence")
PSAI segment decline pulls down Dr Reddy's Q1 show
Earnings were driven by one-off gains
 "PSAI segment decline pulls down Dr Reddy's Q1 show")
Dr Reddy's stock: Product pipeline should boost revenue growth in FY19
Analysts at Nomura believe there is a strong probability that the company will get approval in the near term for Suboxone & expect initially lower competitive intensity
 "Dr Reddy's stock: Product pipeline should boost revenue growth in FY19")
